For investors in Singapore

Horizon Biotechnology Fund

ISIN
LU1897414303

NAV
USD 15.21
As of 25/01/2022

1-Day Change
USD 0.25 (1.67%)
As of 25/01/2022

Morningstar Rating

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, in any country.

Less

Note: You should not make investment decisions based solely on marketing materials. You should read the Prospectus and the Product Highlights Sheet of the Fund for more details of the investment risks and seek independent professional advice where appropriate.

ABOUT THIS FUND

  • Invests globally in companies strategically aligned with environmental and social megatrends: climate change, resource constraints, growing populations, and ageing populations
  • Avoids investing in fossil fuels and companies that stand to be disrupted by the transition to a low-carbon economy
  • Experienced team of global equity investors employing a long-term approach and disciplined fundamental analysis

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Global Life Sciences | Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, PhD, CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Cumulative & Annualised Performance (%)
As of 31/12/2021
A2 USD (Net) A2 USD (With Sales Charge)* NASDAQ Biotechnology Total Return
 
  Cumulative Annualised
1MO 3MO 6MO YTD 1YR 3YR 5YR 10YR Since Inception
10/12/2018
A2 USD (Net) 2.25 -5.69 -3.93 -5.17 -5.17 27.24 - - 23.48
A2 USD (With Sales Charge)* -2.86 -10.41 -8.73 -9.92 -9.92 25.09 - - 21.43
NASDAQ Biotechnology Total Return -1.23 -6.85 -7.86 0.02 0.02 16.52 - - 13.52
FEE INFORMATION
Initial Charge 5.00%
Annual Charge 1.20%
Ongoing Charge
(As of 30/06/2021)
1.92%
Performance Fee 20% of the 'Relevant Amount'

Portfolio

Top Holdings (As of 30/11/2021)
% of Fund
Sarepta Therapeutics 4.70
Vertex Pharmaceuticals 3.26
Ascendis Pharma 2.72
EyePoint Pharmaceuticals 2.62
Neurocrine Biosciences 2.19
Biohaven Pharmaceutical 2.07
Argenx 1.96
Alnylam Pharmaceuticals 1.96
Horizon Therapeutics 1.94
BioMarin Pharmaceutical 1.86

Documents